X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)

CUSIP: 98420X103

Q4 2022 13F Holders as of 31 Dec 2022

Holder snapshot 7 signals
Share change
+21,807,038
Put/Call ratio
135%
SEC-reported price per share
$0.99
Number of holders
52
Value change
+$20,545,513
Number of buys
29
Open additional details 1 more signal available
Number of sells
20
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
94,372,096

Security key

98420X103

Report period

Q4 2022

Institutions

52

Top holders

10

Ownership snapshot

Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
NEA Management Company, LLC
Disclosed value leader
NEA Management Company, LLC
Comparable rows
0/15
Latest evidence
30 Sep 2022
13F Highest disclosed value: $11,155,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

NEA Management Company, LLC has the largest disclosed position value at $11.16M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens NEA Management Company, LLC's linked filing trail.
Disclosed position value Top 5
NEA Management Company, LLC $11.16M
Bain Capital Life Sciences Invest... $10.93M
ORBIMED ADVISORS LLC $8.6M
AXA S.A. $7.06M
VANGUARD GROUP INC $5.49M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
NEA Management Company, LLC
13F
Company
13F
—
denominator unverified
$11,155,000
6,523,157 shares
— 30 Sep 2022
Bain Capital Life Sciences Investors, LLC
13F
Company
13F
—
denominator unverified
$10,926,000
6,389,436 shares
— 30 Sep 2022
ORBIMED ADVISORS LLC
13F
Company
13F
—
denominator unverified
$8,596,000
5,026,817 shares
— 30 Sep 2022
AXA S.A.
13F
Company
13F
—
denominator unverified
$7,056,247
4,126,460 shares
— 30 Sep 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$5,486,000
3,208,103 shares
— 30 Sep 2022
Point72 Asset Management, L.P.
13F
Company
13F
—
denominator unverified
$4,354,000
2,546,446 shares
— 30 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
52
Shares
60,622,175
Rows available
52
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q1 2026 Across Filers

Q1 2026 holders
2
Q4 2022 holders
52
Holder diff
50
Investor Q1 2026 Shares Q4 2022 Shares Share Diff Share Chg % Q1 2026 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .